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Abstract
 
Interleukin (IL)-13 is a key mediator of tissue fibrosis caused by T helper cell type 2 inflamma-
tion. We hypothesized that the fibrogenic effects of IL-13 are mediated by transforming
 
growth factor (TGF)-
 
 
 
. To test this hypothesis we compared the regulation of TGF-
 
 
 
 in
lungs from wild-type mice and CC10-IL-13 mice in which IL-13 overexpression causes pul-
monary fibrosis. IL-13 selectively stimulated TGF-
 
 
 
1
 
 production in transgenic animals and
macrophages were the major site of TGF-
 
 
 
1 
 
production and deposition in these tissues. IL-13
also activated TGF-
 
 
 
1 
 
in vivo. This activation was associated with decreased levels of mRNA
encoding latent TGF-
 
 
 
–binding protein-1 and increased mRNA encoding urinary plasmino-
gen activator, matrix metalloproteinase (MMP)-9, and CD44. TGF-
 
 
 
1 
 
activation was abro-
gated by the plasmin/serine protease antagonist aprotinin. It was also decreased in progeny of
crosses of CC10-IL-13 mice and MMP-9 null mice but was not altered in crosses with CD44
null animals. IL-13–induced fibrosis was also significantly ameliorated by treatment with the
TGF-
 
 
 
 antagonist soluble TGF
 
 
 
R-Fc (sTGF
 
 
 
R-Fc). These studies demonstrate that IL-13 is
 
a potent stimulator and activator of TGF-
 
 
 
1
 
 in vivo. They also demonstrate that this activation
is mediated by a plasmin/serine protease- and MMP-9–dependent and CD44-independent
mechanism(s) and that the fibrogenic effects of IL-13 are mediated, in great extent, by this
TGF-
 
 
 
 pathway.
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Introduction
 
Tissue fibrosis is a well-documented consequence of Th2
cytokine-dominated inflammatory responses. This is nicely
illustrated in asthma where Th2-dominated inflammation is
the cornerstone of the disorder (1, 2) and airway remodel-
ing with subepithelial fibrosis are believed to be adverse
consequences of this inflammatory response (for a review,
see reference 3). Th2 inflammation also plays a central role
in the pathogenesis of a variety of other fibrotic disorders
including progressive systemic sclerosis (4–6), idiopathic
 
pulmonary fibrosis (IPF
 
*
 
; references 5–8), radiation-
induced pulmonary fibrosis (9), chronic lung allograft re-
jection (10), bleomycin lung (11), and hepatic fibrosis (12–
15)
 
. 
 
In vitro polarized Th2 cells also induce tissue fibrosis
when passively transferred and activated in vivo (16). In
contrast, Th1 cytokine-dominated responses eventuate in
tissue fibrosis less frequently and IFN-
 
 
 
, the prototypic
Th1 cytokine, has a variety of antifibrotic effector proper-
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–binding protein; MMP, matrix me-
talloproteinase; PAI, plasminogen activator inhibitor; RT, reverse
transcription; s, soluble; uPA, urokinase type plasminogen activator; WT,
wild-type. 
810
 
IL-13 Stimulates and Activates TGF-
 
 
 
1
 
ties and has been shown to be a useful antifibrotic agent in
murine and human pulmonary and renal fibrotic disorders
(8, 17–19). As a result of these findings, the “type 2 cyto-
kine hypothesis of fibrosis” has been formulated which sug-
gests that fibrosis occurs when cytokine balance shifts in a
Th2 (type 2) direction (19). Surprisingly, the mechanism(s)
by which Th2 inflammation generates tissue fibrosis is
poorly understood. In addition, although it is assumed in
this hypothesis that Th2 cytokines induce fibrosis via path-
ways that are independent of known mediators of fibrosis
such as TGF-
 
 
 
, the validity of this assumption has not been
adequately assessed.
IL-13 is a pleiotropic cytokine produced by a gene on
chromosome 5 at q31 that is elaborated in significant quan-
tities by appropriately stimulated Th2 cells (20, 21). A vari-
ety of lines of evidence have demonstrated that IL-13 is an
important mediator in the pathogenesis of asthma (22–25).
IL-13 has also been implicated in the pathogenesis of he-
patic fibrosis, progressive systemic sclerosis, pulmonary fi-
brosis, and nodular sclerosing Hodgkin’s disease (4, 12, 13,
26–28). In these diseases IL-13 is felt to contribute to the
pathogenesis of tissue fibrosis. This is based on studies from
our laboratory that demonstrated that the transgenic over-
expression of IL-13 in the murine airway causes subepithe-
lial airway fibrosis that is similar, in many ways, to the fi-
brotic response seen in remodeled human asthmatic airways
(3, 25). It is also based on studies that demonstrate that IL-
13 is the primary cytokine responsible for hepatic fibrosis in
murine schistosomiasis and that IL-13 is a potent stimulator
of fibroblast proliferation and collagen production in vitro
(12, 13, 29, 30). Surprisingly, the mechanism of IL-13–
induced fibrosis has not been further defined. In addition,
the relationship between IL-13 and TGF-
 
 
 
 cytokines,
which are also dysregulated in many of these disorders,
have not been elucidated.
We hypothesized that IL-13 mediates its fibrogenic ef-
fects in the lung and other organs by altering TGF-
 
 
 
 cyto-
kine homeostasis. To test this hypothesis we characterized
the regulation and role of TGF-
 
 
 
 moieties in lungs from
wild-type (WT) mice and transgenic CC10-IL-13 mice in
which the overexpression of IL-13 causes airway and pa-
renchymal fibrosis (25). These studies demonstrate that IL-
13 selectively stimulates and activates TGF-
 
 
 
1
 
. They also
define the mechanism of this TGF-
 
 
 
1
 
 activation and dem-
onstrate that the fibrotic effects of IL-13 are mediated, in
great extent, by this TGF-
 
 
 
1
 
 induction and activation
pathway.
 
Materials and Methods
 
Genetically Manipulated Mice.
 
CC10-IL-13 mice, mice with
homozygous null mutations of matrix metalloproteinase (MMP)-
9
 
 
 
/
 
 
 
, and mice with homozygous null mutations of CD44
(CD44
 
 
 
/
 
 
 
) were used in these studies. In the CC10-IL-13 mice,
the Clara cell 10-kDa (CC10) promoter was used to constitu-
tively overexpress IL-13 in a lung-specific fashion. The methods
that were used to generate these mice in our laboratory and the
organ specificity of transgene expression, levels of bronchoalveo-
 
lar lavage (BAL) IL-13, and the phenotype of these animals have
been described previously (25). The MMP-9
 
 
 
/
 
 
 
 mice were also
generated in our laboratories (31). MMP-9 is inactivated in these
mice as a result of the insertion of NEO genes in exon-2 of each
MMP-9 allele. CD44
 
 
 
/
 
 
 
 mice were obtained from T. Mak (Am-
gen Institute, Toronto, Canada; reference 32). CC10-IL-13 mice
with homozygous null mutations of MMP-9 (CC10-IL-13/
MMP-9
 
 
 
/
 
 
 
) or CD44 (CC10-IL-13/CD44
 
 
 
/
 
 
 
) were generated
by breeding CC10-IL-13 transgene (
 
 
 
) mice with MMP-9
 
 
 
/
 
  
 
or
CD44
 
 
 
/
 
 
 
 animals. Unless otherwise indicated, WT littermates
(
 
 
 
/
 
 
 
) were used as negative controls.
 
BAL.
 
After anesthesia, a median sternotomy was performed
and the trachea was exposed by blunt dissection. A 22-gauge
catheter was inserted into the trachea, and BAL was performed
by instilling 1 ml of PBS into the trachea and gently aspirating
back. This was repeated twice. The BAL samples from each ani-
mal were pooled and centrifuged. Differential cell counts were
performed on the pellet and the supernatant was stored at 
 
 
 
20
 
 
 
C
until used.
 
Histologic Evaluation.
 
Histologic evaluation was performed as
described previously (25, 33, 34). In brief, animals were killed, a
median sternotomy was performed, and right heart perfusion
was accomplished with calcium- and magnesium-free PBS to
clear the pulmonary intravascular space. The heart and lung
were then removed en bloc, fixed to pressure (25 cm) with neu-
tral buffered formalin, incubated overnight in formalin, embed-
ded in paraffin, sectioned, and stained. Hematoxylin and eosin,
Mallory’s Trichrome, and Sirius red staining were performed in
the Research Pathology Laboratory at Yale University, New
Haven, CT.
 
Treatment with Soluble TGF-
 
  
 
Type II Receptor-Fc and Aproti-
nin.
 
The role of TGF-
 
 
 
 was assessed using soluble TGF
 
 
 
R-Fc
(sTGF
 
 
 
R-Fc). This TGF-
 
 
 
 antagonist contains a soluble TGF-
 
 
 
type II receptor attached to the Fc fragment of human IgG. The
generation protocols and in vitro and in vivo efficacy of this con-
struct have been described previously (35, 36). It was adminis-
tered to IL-13 transgene (
 
 
 
) and littermate control mice in PBS
(2 mg/kg) by intraperitoneal injection every other day for 8 wk,
starting when the mice were 4 wk old. An equivalent dose of
pooled human IgG was used as a control.
Aprotinin from bovine lung (6618 KIU/mg) was purchased
from ICN Inc. It was administered to IL-13 transgene (
 
 
 
) mice
and littermate controls (500
 
  
 
g/mouse) by intraperitoneal injec-
tion every day for 4 wk starting when the mice were 4 wk of age.
An equivalent dose of PBS was administered according to the
same schedule as a vehicle control.
 
mRNA Analysis.
 
mRNA levels were assessed using reverse
transcription (RT)-PCR and ribonuclease protection assays as
described previously by our laboratories (33, 37). In these experi-
ments, total lung RNA was obtained using TRIzol reagent (Life
Technologies) as per the manufacturer’s instructions followed by
treatment with DNase I (Ambion, Inc.). In the RT-PCR assays,
0.5 
 
 
 
g of RNA was reverse transcribed to cDNA and gene-spe-
cific primers (Table 1) were used to amplify selected regions of
each target moiety. The primers and optimum conditions used in
the reactions were designed according to published sequences.
The whole reaction was performed in a 25 
 
 
 
l volume using an
Access RT-PCR kit purchased from Promega according to the
manufacturer’s instructions. All primers were synthesized at the
Yale Oligonucleotide Synthesis Laboratory. To verify that equal
amounts of undegraded RNA were added in each RT-PCR re-
action, 
 
 
 
-actin was used as an internal standard. Amplified PCR
products were detected using 1.2% agarose ethidium bromide gel 
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electrophoresis, quantitated electronically, and confirmed by nu-
cleotide sequencing. Ribonuclease protection assays were per-
formed using the RiboQuant In Vitro Transcription kit (BD
PharMingen) according to manufacturer’s instructions.
 
Quantification of TGF-
 
 
 
1.
 
The levels of immunoreactive
TGF-
 
 
 
1 
 
and TGF-
 
 
 
2 
 
were determined with cytokine-specific
commercial ELISA kits as per the manufacturer’s instructions
(R&D Systems).
 
Immunohistochemistry.
 
Immunostains for TGF-
 
 
 
1
 
 was per-
formed on paraffin-embedded tissues that had been fixed in either
Streck’s tissue fixative or neutral buffered 4% formalin. After sec-
tioning the tissues were rehydrated, endogenous peroxidase was
blocked by quenching with H
 
2
 
O
 
2 
 
and methanol and the tissues
were treated in a microwave oven in the presence of citrate
buffer (10 mM, pH 6.0) for 9 min (3 cycles of 3 min each). After
preblocking with Dako blocking reagent (Dako) for 15 min,
polyclonal rabbit anti–TGF-
 
 
 
1
 
 antibody (Santa Cruz Biotechnol-
ogy, Inc.) was applied at a 1:100 dilution. In experiments de-
signed to see if an appropriate peptide competed for antibody
binding, the anti–TGF-
 
 
 
1
 
 antiserum was preincubated with mu-
rine TGF-
 
 
 
1
 
 (R&D Systems) at a 1:1 molar ratio for 2 h before it
was applied to the tissues. After overnight incubation at 4
 
 
 
C, the
tissues were rinsed with PBS/0.1% Tween 20 and Envision
(Dako) peroxidase coupled anti–rabbit secondary reagent was
applied for 30 min. The slides were then washed, 3,3
 
 
 
diami-
nobenzidine was applied for 5 min, and the tissues were counter-
stained with hematoxylin.
 
In Situ Hybridization.
 
Lung tissue was fixed in formaldehyde
and processed into paraffin. 5 
 
 
 
 sections were cut, deparaffinized,
treated with proteinase K (20 
 
 
 
g/ml) for 20 min at 37
 
 
 
C fol-
lowed by 0.1 M triethylnolamine/0.25% acetic anhydride, pH
8.0, for 10 min at room temperature, and then rinsed in PBS.
The mouse TGF-
 
 
 
1
 
 probe (containing the segment from the
mouse TGF-
 
 
 
1
 
 sequence between base pairs 1027–1465; Gen-
Bank Accession, NM-011577) was placed in a pBluescript II KS
phagemid (Stratagene) between T7 and T3 promoter sites. Sense
and antisense RNA probes were generated, labeled with a digox-
igenin RNA labeling kit (Roche), denatured at 65
 
 
 
C, added to
commercially available hybridization buffer (Ambion) at 6 ng/
 
 
 
l,
and the hybridization mixture was incubated with tissue over-
night at 52
 
 
 
C. The tissues were then washed twice with 4
 
 
 
SSC
for 5 min at room temperature, twice with 2
 
 
 
SSC for 10 min at
37
 
 
 
C, and incubated with RNase A (10
 
  
 
g/ml) for 45 min at
37
 
 
 
C. This was followed by 2 10-min washes in 2
 
 SSC at room
temperature and 3 20-min washes in 0.2 SSC at 50 C. Probe
was detected by overnight incubation with sheep antibodies to
digoxigenin-labeled with alkaline phosphatase (Roche) followed
by 4-nitroblue tetrazolium chloride/5-bromo-4-chloro-3-indoyl-
phosphate (BCIP/NBT) as described by the manufacturer.
TGF-  Bioassay. To measure the bioactivity of TGF-  in
BAL fluids, we used mink lung epithelial cells permanently trans-
fected with a construct containing the TGF-  responsive human
plasminogen activator inhibitor (PAI)-1 promoter fused to a lu-
ciferase reporter gene (TMLC, a gift from John Munger, NYU
Medical Center, New York, NY). These cells were seeded into
wells of 12-well tissue culture plates (105 cells per well per millili-
ter) in DMEM supplemented with 10% FCS and allowed to at-
tach for 5 h. They were then washed and incubated in triplicate
in mixtures containing 200  l of BAL fluid and 800  l of assay
medium (DMEM with 2.5% FCS). These incubations were per-
formed in the presence and absence of saturating quantities of
neutralizing antibodies specific for TGF- 1, TGF- 2, or TGF- 3
Table I. Primer Sequences and RT-PCR Conditions
Gene s/as Primer Sequences (5  to 3 )
Anneal. 
Tm. Cycle Product Size (bp) GenBank Accession Number
LTBP-1 s GGTGTGTGGATGTGAACGAG 60 C 30 447 AF022889
as CTCCAAACAGCAAGCATTCA
CD36 s GCAAAGAAGGAAAGCCTGTG 60 C 30 337 L23108
as TCTACCATGCCAAGGAGCTT
TSP-1 s GACGTCGATGAGTGCAAAGA 60 C 27 532 M87276
as AGTCATACTGGGCTGGGTTG
INT- 6 s AGGGGTGACTGCTATTGTGG 60 C 30 423 AF115376
as GGCACCAATGGCTTTACACT
uPA s CCTACAATGCCCACAGACCT 60 C 25 471 NM-008873
as GCTGCTCCACCTCAAACTTC
PAI-1 s TCATCAATGACTGGGTGGAA 60 C 30 539 M33960
as CTGCTCTTGGTCGGAAAGAC
MMP-9 s CCATGAGTCCCTGGCAG 58 C 30 505 X72795
as ATGACAATGTCCGCTTCG
CD-44 s GAGGATTCATCCCAACGCTA 60 C 25 499 M27129
as GGTCACTCCACTGTCCTGGT
 -actin s GTGGGCCGCTCTAGGCACCA 65 C 20 241 X03672
as TGGCCTTAGGGTTCAGGGGG
Anneal. Tm., annealing temperature; as, antisense; INT, integrin; s, sense; TSP, thrombospondin.812 IL-13 Stimulates and Activates TGF- 1
(R&D Systems). The luciferase activities in these cells were mea-
sured 16 h later using the Luciferase Assay System (Promega) ac-
cording to the manufacturer’s instructions. The bioactivity attrib-
uted to TGF- 1  (TGF- 1  bioactivity) was defined as the
difference in the luciferase activities of identical cells incubated in
the absence and presence of anti–TGF- 1.
Western Blot Analysis. BAL fluids were concentrated fivefold
using Centricon 10 concentrators (Amicon). Equal volumes of
test and control samples were fractionated on 15% SDS-PAGE
gels under reducing conditions and transferred to PVDF mem-
branes (Millipore). The membranes were then blocked with 5%
nonfat dry milk, washed three times with PBS/0.1% Tween 20,
and incubated for 1 h at room temperature in a 1:200 dilution of
rabbit polyclonal anti–TGF- 1, anti–TGF- 2, or anti–TGF- 3
antibodies (Santa Cruz Biotechnology, Inc.). After washing with
PBS/ 0.1% Tween 20, they were incubated for 1 h with a horse-
radish peroxidase-conjugated donkey anti–rabbit antibody (Am-
ersham Pharmacia Biotech), rewashed in PBS/0.1% Tween 20,
and protein bands were detected using the ECL Western blot de-
tection system (Amersham Pharmacia Biotech).
Collagen Assay. Total lung collagen content was determined
by quantifying total soluble collagen using the Sircol Collagen
Assay kit (Biocolor) according to the manufacturer’s instruc-
tions. Briefly, lungs were homogenized in 5 ml of 0.5 M acetic
acid containing 1 mg pepsin (Sigma-Aldrich)/10 mg tissue resi-
due. Each sample was incubated for 24 h at 4 C with stirring.
After centrifugation, 100 µl of each supernatant was assayed. 1
ml of Sircol dye reagent that specifically binds to collagen was
then added to each sample and mixed for 30 min. After centrifu-
gation the pellet was suspended in 1 ml of alkali reagent (0.5 M
NaOH) included in the kit and optical density evaluated at 540
nm with a spectrophotometer. The values in the test samples
were compared to the values obtained with collagen standard so-
lutions provided by the manufacturer that were used to con-
struct a standard curve.
Picosirius Red Staining and Evaluation. Collagen content was
assessed using Picosirius red staining. This approach was chosen
because it accurately reflects organ collagen content assessed with
hydroxyproline assays (38, 39) and allows areas of localized col-
lagen accumulation to be specifically evaluated. In these assays,
sections of lung are stained with Sirius red as described previously
(40). For examination of lung parenchyma, the tissue was exam-
ined under polarized light with an Olympus BH-2 microscope
with an original magnification: 2  objective. This magnification
allows virtually the entire lung section to be acquired for analysis
using 4–6 fields. Image acquisition was performed with a DXC-
970MD Sony video camera attached to a iXTV video capture
card (IXMICRO) in a G3 Macintosh (Apple Computer) using
software included with the card. Images are captured as grey scale
TIFF encoded video clips. These are opened in NIH Image and
averaged to reduce noise. Images are then subject to 2-D rolling
ball background subtraction to make the background uniform.
Areas of parenchyma are manually outlined to exclude airways
and large vessels, then thresholded. The number of white versus
total pixels are then recorded. The total number of white pixels
versus total pixels examined is a reflection of collagen density.
For examination of airway fibrosis, images were acquired with
an original objective: 4  objective. Only airways that were oval
or circular and are outside the central bronchovascular sheath
were analyzed. Each field was acquired as a regular color image as
well as a polarized image. Images were opened within NIH Im-
age. The airway was outlined using the color image to determine
area and minor axis. The same airway was outlined in the polar-
ized image and subject to thresholding to determine the number
of white pixels. Data was expressed as area of collagen versus total
airway area.
Statistics. Normally distributed data are expressed as means  
SEM and assessed for significance by Student’s t test or ANOVA
as appropriate. Data that were not normally distributed were as-
sessed for significance using the Wilcoxon rank sum test.
Results
Effect of IL-13 on TGF- 1 Production. Pulmonary fibro-
sis was a prominent finding in CC10-IL-13 mice. As previ-
ously reported, subepithelial and adventitial airway fibrosis
were readily appreciated in 1-mo-old animals (25). This re-
sponse continued to progress over the life of the mouse. By
the time the mice were 2–3 mo of age, parenchymal fibro-
sis was also appreciated (Fig. 1). To gain insight into the
mechanisms of this fibrotic response, studies were under-
taken to determine if IL-13 stimulated the production of
TGF-  moieties in the murine lung. Our initial studies
used ribonuclease protection assays to compare the levels of
TGF- 1, TGF- 2, and TGF- 3 mRNA in lungs from
transgene ( ) and transgene ( ) animals. As can be seen in
Fig. 2, IL-13 caused an impressive increase in the levels of
mRNA encoding TGF- 1. Comparable increases in the
levels of mRNA encoding TGF- 2 were not appreciated.
In addition, the levels of TGF- 3 in lungs from transgene
( ) mice were lower than the levels in their transgene ( )
littermate controls (Fig. 1).
Studies were next undertaken to determine if the in-
creased levels of TGF- 1 mRNA in lungs from transgene
( ) mice were associated with increased levels of BAL fluid
TGF- 1 protein. Using an ELISA assay that detects bioac-
tive cytokine, TGF- 1  was not detected in significant
quantities in acid-treated BAL fluids from transgene ( )
animals (Fig. 3 A). Significantly increased levels of TGF- 1
were noted in acid-treated BAL from 1-mo-old transgene
( ) animals and the levels of BAL TGF- 1 continued to
increase as the animals aged (Fig. 3 A). In contrast, TGF- 2
was not detected by ELISA in BAL fluids from transgene
( ) or ( ) animals (data not shown). In accord with these
findings, TGF- 1 monomers were readily detected in im-
munoblots performed with acid-treated BAL fluids from
transgene ( ) mice but were not readily apparent in BAL
fluids from transgene ( ) littermate controls (see Fig. 3 B).
Comparable alterations in the levels of TGF- 2 and TGF-
 3 proteins were not noted in comparisons of immunoblots
from acid-activated BAL fluids from transgene ( ) and ( )
mice (data not shown). When viewed in combination,
these findings demonstrate that IL-13 selectively stimulates
TGF- 1 mRNA accumulation and protein production in
the murine lung.
Localization of TGF- 1 in IL-13 Transgenic Mice. To
gain insight into the mechanism(s) of TGF- 1 induction,
immunohistochemistry and in situ hybridization (ISH)
were used to localize and define the sites of TGF- 1 pro-
duction in lungs from transgene ( ) and transgene ( ) ani-
mals. TGF- 1 protein and mRNA were readily apparent in813 Lee et al.
airway epithelial cells in lungs from transgene ( ) animals.
Low levels of TGF- , mRNA, and protein were also
noted in some alveolar macrophages (Figs. 4 and 5 and data
not shown). In lungs from IL-13 transgene ( ) mice im-
pressive increases in macrophage TGF- 1 mRNA and pro-
tein were readily apparent. Lower levels of TGF- 1
mRNA and protein could also be appreciated in type II al-
veolar epithelial cells, airway epithelial cells, and occasion-
ally in eosinophils from these transgene ( ) animals (Figs. 4
and 5 and data not shown). In these immunohistochemical
evaluations, preincubation of our primary antibody with
TGF- 1 peptide effectively abrogated the detection of
TGF- 1 in these tissues (Fig. 4). In the ISHs, significant
staining with the sense probe was not noted (Fig. 5). This
demonstrates the specificity of these approaches. Thus, lung
macrophages are the major sites of production and storage,
and airway and alveolar epithelial cells and eosinophils are
lesser sites of production and storage of TGF- 1 in lungs
from IL-13 transgene ( ) animals.
Effect of IL-13 on TGF- 1 Activation. TGF-  cyto-
kines are produced as biologically inactive moieties with
the TGF- 1 dimer bound to its propeptide, latency-associ-
ated peptide (LAP). They exert their tissue effects after ac-
tivation, a complex process that likely involves proteolysis
Figure 1. Histologic responses in
CC10-IL-13 mice. H&E stains are used in
A and C to compare the histologic fea-
tures of WT littermate control mice and
3-mo-old CC10-IL-13 transgene ( )
mice respectively. Trichrome stains are
used in B and D to compare the collagen
in WT littermate control mice and 3-mo-
old transgene ( ) animals respectively. All
figures are at original magnification: 20 .
Collagen stains blue in these panels.
Figure 2. Effect of IL-13 on TGF-  cytokine mRNA. Whole lung
RNA from IL-13 transgene ( ) mice and transgene ( ) littermate con-
trols were obtained. The levels of mRNA encoding TGF- 1, TGF- 2,
TGF- 3, and L32, the housekeeping control gene, were assessed using ri-
bonuclease protection assays. Each lane represents an individual animal.
Figure 3. Effect of IL-13 on TGF- 1 protein. In A, BAL fluids were
obtained from 1–3-mo-old transgene ( ) (black bars) and transgene ( )
(hatched bars) mice and acid treated. The levels of total TGF- 1 in these
fluids were characterized by ELISA. The noted values represent the
mean   SEM of a minimum of four animals. *P   0.01, **P   0.001
versus WT mice. In B, BAL fluids were obtained from 2-mo-old trans-
gene ( ) and ( ) mice and acid activated. BAL TGF- 1 was then assessed
by immunoblot analysis. Each lane represents an individual animal.814 IL-13 Stimulates and Activates TGF- 1
in vivo and occurs in biologic fluids in vitro after local
acidification (41–45). Studies were thus undertaken to de-
termine if the TGF- 1 in BAL fluids from IL-13 transgene
( ) mice was produced in a biologically inactive or sponta-
neously activated form. This was done by comparing the
TGF- 1 bioactivities in BAL fluids from transgene ( ) and
transgene ( ) mice using the TMLC/PAI-1 promoter-
based luciferase bioassay that only responds to activated
TGF-  moieties. As can be seen in Fig. 6, significant TGF-
 1 bioactivity was not present in the untreated or acid-
treated BAL fluids from transgene ( ) mice. In contrast,
impressive levels of spontaneous TGF- 1 bioactivity were
present in untreated BAL fluids from IL-13 transgene ( )
animals (Fig. 6 A). Latent TGF- 1 was also present since
acidification revealed an impressive additional increase in
the levels of TGF- 1 bioactivity in BAL fluids from trans-
gene ( ) animals (Fig. 6 B). When viewed in combination,
these studies demonstrate that IL-13 increases the produc-
tion and activates TGF- 1 in the murine lung.
IL-13 Regulation of Processes Involved in TGF- 1 Activa-
tion. Studies were next undertaken to elucidate the
mechanism(s) by which IL-13 activated the TGF- 1 in
lungs from transgene ( ) mice. A variety of complex
mechanisms of TGF- 1 activation have been described
previously. They include pathways involving CD36 and
thrombospondin-1 (46, 47), urokinase type plasminogen
activator (uPA, and its inhibitor PAI-1) (41, 43, 46, 48,
49), the  V 6 integrin (44), latent TGF- –binding protein
(LTBP)-1 (50), and CD44 and MMP-9 (51). To determine
if these pathways were activated in IL-13 transgenic mice,
we quantitated the levels of mRNA encoding key elements
of these pathways in lungs from transgene ( ) and trans-
gene ( ) animals. Similar levels of mRNA encoding
CD36, thombospondin-1, the  6 integrin and PAI-1 were
seen in whole lung RNA from transgene ( ) and transgene
( ) animals (Fig. 7). In contrast, an impressive decrease in
the levels of mRNA encoding LTBP-1 and significant in-
creases in the levels of mRNA encoding uPA, MMP-9,
and CD44 were noted (Fig. 7).
Role of uPA/Serine Proteinases in TGF- 1 Activation.
Because the levels of mRNA encoding uPA were increased
in IL-13 transgene ( ) animals, studies were undertaken to
determine if uPA (or related serine proteinases) played im-
portant roles in the activation of TGF- 1 in lungs from IL-
Figure 4. Immunohistochemical
localization of TGF- 1. Immunohis-
tochemistry was used to localize the
sites of TGF- 1 in WT transgene ( )
mice and CC10-IL-13 transgene ( )
animals (2–3 mo of age). Epithelial
TGF- 1  can be appreciated in the
transgene ( ) animals (A, original
magnification: 20 ). Macrophage
TGF- 1 is increased (C, original mag-
nification: 20  and E, original magni-
fication: 40 , black arrows), and alve-
olar type II epithelial cell (F, original
magnification: 40 , white arrows)
and eosinophil (F, 40 , black arrow)
TGF- 1 can be appreciated in IL-13
transgene ( ) animals. In all cases,
preincubation with TGF-   peptide
abrogated TGF- 1 staining (B and D,
original magnification: 20 ).815 Lee et al.
13 transgene ( ) mice. In these experiments we compared
the levels of spontaneously bioactive and total TGF- 1 in
BAL fluids from lungs from transgene ( ) mice that had
been treated with the plasmin/serine proteinase antagonist
aprotinin or an appropriate vehicle control. Significant lev-
els of spontaneously active or acid activatable TGF- 1 were
not noted in BAL fluids from transgene ( ) mice that re-
ceived aprotinin or vehicle control (Fig. 8). Aprotinin did,
however, totally abrogate the spontaneous activation of
TGF- 1 in BAL fluids from IL-13 transgene ( ) mice (Fig.
8). This decrease was out of proportion to the modest de-
crease in the levels of total TGF- 1 in the same BAL fluids
(Fig. 8). These studies demonstrate that uPA-like serine
proteinases, play a critical role in IL-13–induced TGF- 1
activation in this in vivo system.
Role of MMP-9 and CD44 in IL-13-induced TGF- 1 Acti-
vation. MMP-9 can activate TGF-  cytokines when pre-
sented on cell surface CD44 molecules (51). Thus, to
define the role of MMP-9 in TGF- 1 activation, CC10-
IL-13 transgene ( ) mice were bred with mice with null
mutations of MMP-9 or CD44. The spontaneous and total
TGF- 1 bioactivity in BAL fluids from CC10-IL-13 mice
with WT and null MMP-9 or CD44 loci were then com-
pared. Spontaneously bioactive TGF- 1 was not noted in
BAL fluids from WT transgene ( ) littermate control ani-
mals or animals with null mutations of MMP-9 or CD44
(Fig. 9 and data not shown). As noted above, spontaneously
bioactive TGF- 1 was noted in untreated BAL fluids from
CC10-IL-13 transgene ( ) mice with WT MMP-9 loci
(Fig. 9). Interestingly, null mutations of MMP-9 caused a
significant decrease in the levels of spontaneously active
TGF- 1 in BAL fluids from CC10-IL-13 transgene ( )
mice (Fig. 9 A). Overall, BAL fluids from CC10-IL-13/
MMP-9 /  mice contained 57   5% as much TGF- 1
bioactivity as BAL fluids from CC10-IL-13/MMP-9 / 
animals (P   0.01). This decrease in TGF- 1 bioactivity
was not due to a decrease in IL-13 elaboration or total
TGF- 1 production since similar levels of BAL IL-13 and
acid-activatable total TGF- 1were noted in transgene ( )
mice with WT and null MMP-9 loci (Fig. 9 B and data
not shown). CD44 also did not play an essential role in
this MMP-9 effect since similar levels of spontaneously
active TGF- 1 were noted in IL-13 transgenic ( ) mice
with WT and null CD44 loci (data not shown). These
studies demonstrate that MMP-9 plays a critical role in
IL-13–induced TGF- 1 activation, but not in IL-13–
induced stimulation of TGF- 1 production in our trans-
genic system. They also demonstrate that these TGF- 1–
Figure 5. ISHs of TGF- 1. ISH was
used to define the sites of TGF- 1
mRNA expression in transgene ( ) and
IL-13 transgene ( ) mice (2–3 mo old).
Epithelial TGF- 1 mRNA can be appre-
ciated in the transgene ( ) animals (A,
original magnification: 10 ). Enhanced
macrophage (black arrows) and type II al-
veolar epithelial cell (white arrow) TGF- 1
mRNA can be seen in comparisons of pa-
renchymal areas from IL-13 transgene ( )
mice (C, original magnification: 40 )
and transgene ( ) mice (E, original mag-
nification: 40 ). The lack of staining
with the sense probe is seen in B (original
magnification: 10 , transgene [ ]), D
(original magnification: 40 , transgene
[ ]), and E (original magnification: 40 ,
transgene [ ]).816 IL-13 Stimulates and Activates TGF- 1
activating effects of MMP-9 can be seen in the absence of
CD44.
Role of TGF- 1 and TGF- 1 Activation in IL-13–induced
Fibrosis. Qualitative histologic techniques (trichrome
stains), quantitative biochemical approaches, and morpho-
metric assessments of localized collagen deposition were
then used to determine if TGF- 1 played a significant role
in IL-13–induced airway and parenchymal fibrosis. In
these studies we compared these collagen parameters in IL-
13 transgene ( ) mice that were treated with a TGF-  an-
tagonist (sTGF R-Fc), aprotinin (which blocks IL-13–
induced TGF- 1 activation), or their appropriate controls.
Similar amounts of collagen were noted in lungs from WT
littermate control mice that received sTGF R-Fc, aproti-
nin, or their respective controls (data not shown). As noted
above, IL-13 caused an impressive increase in lung col-
lagen content that could be easily appreciated with all
three measurement techniques (Fig. 10 and data not
shown). Histologic and biochemical assessments demon-
Figure 6. Spontaneous and total TGF- 1 bioactivity in BAL fluids
from transgene ( ) and transgene ( ) mice. BAL fluids were obtained
from WT transgene ( ) animals and IL-13 transgene ( ) (IL-13 TG)
mice. The levels of TGF- 1 bioactivity in these fluids were assessed be-
fore (A, spontaneous activity) and after acid activation (B, total activity)
using mink lung cells permanently transfected with constructs containing
the PAI-1 promoter driving a luciferase reporter gene as described in Ma-
terials and Methods. The noted values represent the mean   SEM of a
minimum of four animals in each category. *P   0.001 versus WT.
Figure 7. IL-13 regulation of processes involved in TGF- 1 activation.
Whole lung mRNA was obtained from 2–3-mo-old transgene ( ) and
transgene ( ) mice. The levels of mRNA encoding the noted moieties
were evaluated via RT-PCR. Each lane represents an individual animal.
The genotype of each animal is noted on the top of the figure.
Figure 8. Effect of aprotinin on IL-13-induced TGF- 1 bioactivity.
BAL fluids were obtained from transgene ( ) mice treated from 1 mo of
age to 2 mo of age with aprotinin (  aprotinin) or vehicle control. The
spontaneous (A) and acid-activatable (B) TGF- 1 bioactivity in these flu-
ids are compared to that in BAL fluids from WT transgene ( ) littermate
control animals. The noted values represent the mean   SEM of a mini-
mum of four mice in each group. P   0.01.817 Lee et al.
strated that this increase in lung collagen was reduced al-
most to background levels in CC10-IL-13 mice that re-
ceived sTGF R-Fc (Fig. 10). In addition, the Sirius red
morphometric evaluations demonstrated that this antifi-
brotic effect was readily apparent in both the airway and
parenchymal tissue compartments where collagen was de-
creased 85.5   9 and 81.3   11% respectively after sTG-
F R-Fc administration (P   0.001 for both comparisons).
Importantly, a significant decrease in collagen content was
also seen after aprotinin administration (Fig. 10). Overall,
these studies demonstrate, by multiple methods, that TGF-
 1 is the major mediator of IL-13–induced airway and
parenchymal fibrosis in our in vivo system. They also
demonstrate that this fibrotic response requires TGF- 1
activation which is mediated, at least in part, by a uPA/
serine protease-dependent mechanism.
Discussion
To further understand the mechanism(s) by which IL-13
generates tissue fibrosis, we took advantage of a transgenic
system developed in our laboratory in which the chronic
pulmonary overexpression of IL-13 induces airway and pa-
renchymal tissue fibrosis. By comparing the regulation of
TGF-  cytokines and related proteins in lungs from trans-
gene ( ) mice and transgene ( ) littermate controls, and
comparing the fibrotic responses induced by IL-13 in ani-
mals that received and did not receive TGF-  antagonists,
we were able to define the effects of IL-13 on TGF-  cy-
tokines and the role of TGF-  cytokines in IL-13–induced
fibrosis. These studies demonstrate that IL-13 is a potent
stimulator of TGF- 1. They also demonstrate that IL-13
activates TGF- 1 in vivo and that this activation is medi-
ated by a serine protease/plasmin– and MMP-9–dependent
mechanism. Lastly, these studies demonstrate that the fi-
brotic effects of IL-13 are mediated, at least in part, by this
TGF- 1 induction and activation pathway. When viewed
in combination, these studies highlight a novel relationship
between IL-13 and TGF- 1 which is likely to play a key
role in the pathogenesis of Th2- and IL-13–induced tissue
remodeling responses.
Although there are  30 members of the TGF-  super-
gene family, three moieties (TGF- 1, TGF- 2, and TGF- 3)
are the major moieties involved in mammalian regula-
tory systems (45, 52). These cytokines are products of sep-
arate genes that are differentially regulated and expressed
(53). As a result, studies were undertaken to determine if
IL-13 stimulated these TGF-  moieties in a selective fash-
ion and define the sites of TGF- 1 production and localiza-
tion after this induction. These studies demonstrated that
TGF- 1 is the major moiety induced by IL-13 in our ani-
mals and that TGF- 1 mRNA and protein can be found in
large quantities in macrophages and lesser quantities in
bronchiolar epithelial cells, alveolar type II cells, and eo-
sinophils from these animals. These findings are in accord
with studies that demonstrate that TGF- 1 plays a central
role in the pathogenesis of a variety of fibrotic disorders and
models of these diseases (35, 45, 54, 55) and studies that
demonstrate that macrophages, alveolar epithelial cells, al-
veolar type II epithelial cells, and eosinophils are important
sites of TGF- 1 production and/or localization in murine
models of bleomycin-induced pulmonary fibrosis, human
IPF, and human asthma (49, 54–56). It is important to
point out that these studies do not rule out a role for TGF-
 2 and/or TGF- 3 in the pathogenesis of the phenotype of
our transgenic mice or in other IL-13–associated fibrotic
disorders because TGF- 2 and TGF- 3 are expressed in a
ubiquitous fashion in normal pulmonary tissues (55).
TGF-  moieties are elaborated by a wide array of he-
matopoietic and structural cells (53, 57). In these cells,
TGF- 1 is produced as a propeptide which is proteolyti-
cally processed into its propeptide fragment (LAP) and a
COOH-terminal peptide which forms a disulfide-linked
homodimer (43–45, 50, 58). In virtually all cases, TGF- 1
is elaborated as a biologically inactive latent complex which
Figure 9. Role of MMP-9 in IL-13 activation and induction of
TGF- 1. BAL fluids were obtained from transgene ( ) and transgene
( ) CC10-IL-13 mice with WT ( / ) and null ( / ) MMP-9 loci.
The levels of spontaneous (A) and total (B) TGF- 1 bioactivity in these
BAL fluids were assessed before and after acid activation respectively as
described in Materials and Methods. The noted values represent the
mean   SEM of a minimum of four mice in each group. *P   0.01.818 IL-13 Stimulates and Activates TGF- 1
is formed by the covalent bonding of LAP and the TGF- 
dimer and the linking to LTBP-1 (43–45, 50, 58). The
amino terminal of LTBP-1 is critical for tissue transglutam-
inase cross-linking into matrix. Activation of TGF- 1 is re-
quired for TGF-  effector functions to be appreciated.
This is accomplished via multiple complex mechanisms
that release TGF- 1 from the matrix and cleave and/or in-
duce conformational changes that allow TGF- 1 to bind to
its receptor (41, 43–45, 50, 58). Decreases in the levels of
LTBP-1 (50), plasmin activation (43, 46, 48–50), and path-
ways involving CD-36 and tissue thrombospondin-1 (46,
47), the  V 6 integrin (43) and MMP-9 expressed on cell
surface CD44 molecules (51) can all play important roles in
TGF- 1 activation. In contrast to the majority of models of
pulmonary fibrosis in which only latent TGF- 1 can be de-
tected in BAL fluids, our studies demonstrate that a signifi-
cant amount of the TGF- 1 in the BAL fluids from CC10-
IL-13 transgenic mice is spontaneously bioactive. They also
demonstrate that the levels of mRNA encoding LTBP-1
are markedly diminished and the levels encoding uPA
(which activates plasminogen to bioactive plasmin), MMP-9,
and CD44 are increased in IL-13 transgenic mice. This
suggests that the decrease in LTBP-1 and the increase in
plasmin and MMP-9 play important roles in this activation.
Studies using aprotinin corroborated this speculation since
this well-known plasmin inhibitor (48, 51, 59) totally abro-
gated the ability of IL-13 to spontaneously activate TGF- 1
in the lungs from our transgenic animals. The importance
of MMP-9 was also confirmed by breeding the CC10-IL-
13 transgene ( ) mice with mice with a null mutation of
Figure 10. Effects of sTGF R-Fc and aprotinin on IL-13–induced fibrosis. In the panels on the left 1 mo-old IL-13 transgene ( ) mice were treated
with sTGF R-Fc or control and collagen was assessed with trichrome stains. Comparisons are made of WT littermate transgene ( ) control mice (A),
transgene ( ) mice that received control IgG (B), and transgene ( ) mice that received sTGF R-Fc (C). In the panels on the right Sircol biochemical
assays were used to characterize the effects of sTGF R-Fc or aprotinin on lung collagen content. Comparisons are made of WT littermate transgene ( )
control mice, transgene ( ) mice that received appropriate controls (IL-13) and transgene ( ) mice that received sTGF R-Fc (  sTGF R-Fc) or apro-
tinin (  aprotinin). Each bar represents the mean   SEM of a minimum of four animals. *P   0.01.819 Lee et al.
MMP-9, since the levels of spontaneously bioactive TGF-
 1 in BAL fluids from IL-13 transgene ( ) mice with a null
MMP-9 locus were significantly lower than the levels in
BAL fluids from IL-13 transgene ( ) mice with a WT
MMP-9 locus. Interestingly, the effects on TGF- 1 activa-
tion of aprotinin exceeded the effects of the MMP-9 null
mutation in our transgenic system. uPA-activated plasmin
activates MMP-9, both directly and via an indirect pathway
that involves MMP-3 (60). TGF- 1 is also known to stim-
ulate uPA production (61). Thus, the ability of uPA/plas-
min to active TGF- 1 in lungs from IL-13 transgene ( )
mice may be mediated, in part, via the ability of plasmin to
activate MMP-9. In addition, it is tempting to hypothesize
that the LTBP-1, uPA, plasmin, IL-13, and TGF- 1, in our
transgenic animals, are involved in an amplification loop
that drives tissue fibrosis. In this schema, IL-13 stimulates
TGF- 1 and MMP-9 production and inhibits LTBP-1. IL-
13 also stimulates uPA either directly or via TGF- 1. The
decrease in LTBP-1, increase in uPA-induced plasmin, and
increase in MMP-9 all feedback to activate additional
TGF- 1. The TGF- 1, in turn stimulates the elaboration of
additional uPA and activates additional MMP-9 which ac-
tivates more TGF- 1. The increased levels of active TGF-
 1 then generate additional tissue fibrosis.
An interesting relationship between the hyaluronan re-
ceptor CD44, MMP-9, and TGF-  cytokines has been
documented in in vitro studies using tumor cells and nor-
mal keratinocytes. In these studies CD44 was shown to
provide a docking receptor that localized bioactive MMP-9
to the cell surface, and the CD44-MMP-9 complex was
shown to proteolytically activate latent TGF-  moieties
(51). To determine if similar mechanisms were operative in
vivo, we compared the levels of spontaneously bioactive
TGF- 1 in BAL fluids from IL-13 transgene ( ), IL-13 /
MMP-9 / , and IL-13 /CD44 /  mice. These studies
demonstrated that MMP-9 plays an essential role in IL-13–
induced TGF-  activation since significantly decreased lev-
els of spontaneously bioactive TGF- 1 were noted in BAL
fluids from mice with the null MMP-9 mutation. Surpris-
ingly, similar levels of spontaneous TGF- 1  bioactivity
were found in BAL fluids from IL-13 transgene ( ) mice
with WT ( / ) and null CD44 loci. This demonstrates
that MMP-9 does not require CD44 to activate TGF- 1 in
vivo in the lung. This CD44 independence may reflect the
ability of other molecules to present active MMP-9 on the
surface of cells in this complex in vivo system. Alterna-
tively, MMP-9 may only require CD44 to activate specific
TGF-  moieties since, in vitro, TGF- 2 and TGF- 3 are
more susceptible to activation via the CD44/MMP-9 com-
plex than TGF- 1 (51).
In early studies, IL-13 was noted to have effector prop-
erties that are relevant to Th2 inflammation including the
ability to stimulate IgE production, endothelial VCAM-1
expression, and activate B cells (62–64). More recently, IL-
13 has been shown to be associated with and induce tissue
fibrosis (12, 13, 25). This effect was assumed to be due to
direct effects of IL-13 on fibroblasts since IL-13 stimulates
fibroblast proliferation and collagen production in vitro
(12, 29, 30). Our studies add to our understanding of this
response by demonstrating that IL-13 also stimulates the
production and activates TGF-  in vivo. They also dem-
onstrate that IL-13 induces tissue fibrosis, in great extent,
via this TGF- 1 induction and activation pathway. These
findings have important implications for diseases such as
asthma, IPF, PPS, and hepatic fibrosis which are character-
ized by IL-13 production, increased TGF-  production,
and tissue fibrosis. They suggest that IL-13–stimulated
TGF- 1 production and activation may be a major contrib-
utor to the pathogenesis of the tissue fibrosis seen in these
diseases. They also suggest that IL-13 stimulation and acti-
vation of TGF- 1 may represent a healing response in the
host designed to control and repair IL-13–induced tissue
injury. Lastly, they allow for the speculation that interven-
tions that decrease IL-13–induced TGF- 1  production,
TGF- 1 activation, and/or TGF- 1 effector functions will
have beneficial effects in these and other IL-13–mediated
fibrotic diseases. The latter may be especially important
since our present therapeutic approaches do not control the
tissue fibrosis that is a major contributor to the morbidity
and mortality of these disorders.
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